Charles Schwab
CADX

Charles Schwab’s CADENCE PHARMACEUTICALS, INC COM STK CADX Stock Holding History

Charles Schwab’s Portfolio CADX Stock Details CADX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-133,746
Closed -$1.21M – 3078
2013
Q4 		$1.21M Buy
133,746
+11,292
+9% +$81.5K ﹤0.01% 2178
2013
Q3 		$785K Buy
122,454
+690
+0.6% +$4.39K ﹤0.01% 2337
2013
Q2 		$839K Buy
+121,764
New +$848K ﹤0.01% 2265

Other funds holding CADX

OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Charles Schwab's CADX Position: Q1 2014 in Review

Charles Schwab sold out of CADENCE PHARMACEUTICALS, INC COM STK (CADX) in Q1 2014, closing a stake of 133,746 shares — an estimated $1.21M sold.

Charles Schwab first reported a position in CADX in Q2 2013 and held it in 3 quarters. The position peaked at $1.21M in Q4 2013. 3 funds tracked by Wall St. Rank hold CADX as of Q1 2014.

  • Charles Schwab reported no remaining CADENCE PHARMACEUTICALS, INC COM STK position as of Q1 2014 after selling out during the quarter.
  • Charles Schwab sold 133,746 CADENCE PHARMACEUTICALS, INC COM STK shares in Q1 2014, an estimated $1.21M.
  • Charles Schwab first reported a position in CADENCE PHARMACEUTICALS, INC COM STK in Q2 2013 and held it in 3 quarters.
  • Charles Schwab's CADENCE PHARMACEUTICALS, INC COM STK position peaked at $1.21M in Q4 2013.
  • 3 funds tracked by Wall St. Rank held CADENCE PHARMACEUTICALS, INC COM STK as of Q1 2014.

Based on Charles Schwab's 13F filing for Q1 2014, filed 29 Apr 2014.